Management of Post-transplant Hyperparathyroidism and Bone Disease

Rowena Delos Santos, Ana Rossi, Daniel Coyne, Thin Thin Maw

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Abstract

Significant advances in immunosuppressive therapies have been made in renal transplantation, leading to increased allograft and patient survival. Despite improvement in overall patient survival, patients continue to require management of persistent post-transplant hyperparathyroidism. Medications that treat persistent hyperparathyroidism include vitamin D, vitamin D analogues, and calcimimetics. Medication side effects such as hypocalcemia or hypercalcemia, and adynamic bone disease, may lead to a decrease in the drugs. When medical management fails to control persistent post-transplant hyperparathyroidism, treatment is a parathyroidectomy. Surgical techniques are not uniform between centers and surgeons. Undergoing the surgery may include a subtotal technique or a technique including total parathyroid gland resection with partial heterotopic gland reimplantation. In addition, there are possible post-surgical complications. The ideal treatment for persistent post-transplant hyperparathyroidism is the treatment and prevention of the condition while patients are being managed for their late-stage chronic kidney disease and end-stage renal disease.

Original languageEnglish
Pages (from-to)501-513
Number of pages13
JournalDrugs
Volume79
Issue number5
DOIs
StatePublished - Apr 1 2019

Fingerprint Dive into the research topics of 'Management of Post-transplant Hyperparathyroidism and Bone Disease'. Together they form a unique fingerprint.

Cite this